Chemical–genetic interaction mapping links carbon metabolism and cell wall structure to tuberculosis drug efficacy
Current chemotherapy against Mycobacterium tuberculosis (Mtb), an important human
pathogen, requires a multidrug regimen lasting several months. While efforts have been …
pathogen, requires a multidrug regimen lasting several months. While efforts have been …
Practices of therapeutic drug monitoring in tuberculosis: an international survey
I Margineanu, O Akkerman, D Cattaneo… - European …, 2022 - Eur Respiratory Soc
Tuberculosis (TB) is still one of the top 10 causes of death in low and lower-middle income
countries [1]. TB's long and complex treatment, side-effects, and development of resistant …
countries [1]. TB's long and complex treatment, side-effects, and development of resistant …
Population pharmacokinetics of linezolid in tuberculosis patients: dosing regimen simulation and target attainment analysis
The prolonged treatment duration for multidrug-resistant tuberculosis (MDR-TB) makes
linezolid dosing difficult because of adverse effects associated with long-term use. We …
linezolid dosing difficult because of adverse effects associated with long-term use. We …
Delamanid resistance: update and clinical management
TVA Nguyen, RM Anthony, TTH Cao… - Clinical Infectious …, 2020 - academic.oup.com
Abstract Delamanid, a-first-in-class bicyclic nitroimidazole, was recently approved for
multidrug-resistant tuberculosis treatment. Pitted against the hope for improving treatment …
multidrug-resistant tuberculosis treatment. Pitted against the hope for improving treatment …
FBXO32-mediated degradation of PTEN promotes lung adenocarcinoma progression
FBXO32, a member of the F-box protein family, is known to play both oncogenic and tumor-
suppressive roles in different cancers. However, the functions and the molecular …
suppressive roles in different cancers. However, the functions and the molecular …
[HTML][HTML] Update on the diagnosis and treatment of tuberculosis
F Baquero-Artigao, T Del Rosal, L Falcón-Neyra… - Anales de Pediatría …, 2023 - Elsevier
Abstract According to World Health Organization estimates, more than 1 million patients
aged less than 15 years develop tuberculosis (TB) each year worldwide. In some regions …
aged less than 15 years develop tuberculosis (TB) each year worldwide. In some regions …
Shortened tuberculosis treatment regimens: what is new?
Given the global burden of tuberculosis, shortened treatment regimens with existing or
repurposed drugs are needed to contribute to tuberculosis control. The long duration of …
repurposed drugs are needed to contribute to tuberculosis control. The long duration of …
[HTML][HTML] Actualización del diagnóstico y tratamiento de la tuberculosis
F Baquero-Artigao, T del Rosal, L Falcón-Neyra… - Anales de …, 2023 - Elsevier
Más de un millón de pacientes menores de 15 años desarrollan tuberculosis (TB)
anualmente en el mundo, según estimaciones de la OMS. La TB por cepas resistentes a los …
anualmente en el mundo, según estimaciones de la OMS. La TB por cepas resistentes a los …
A current perspective on the potential of nanomedicine for anti-tuberculosis therapy
K Borah Slater, D Kim, P Chand, Y Xu… - Tropical medicine and …, 2023 - mdpi.com
Tuberculosis (TB) is one of the ten infectious diseases that cause the highest amount of
human mortality and morbidity. This infection, which is caused by a single pathogen …
human mortality and morbidity. This infection, which is caused by a single pathogen …
“One-Two Punch”: Synergistic ß-Lactam Combinations for Mycobacterium abscessus and Target Redundancy in the Inhibition of Peptidoglycan Synthesis Enzymes
DC Nguyen, KM Dousa, SG Kurz… - Clinical Infectious …, 2021 - academic.oup.com
Mycobacterium abscessus subsp. abscessus is one of the most difficult pathogens to treat
and its incidence in disease is increasing. Dual β-lactam combinations act synergistically in …
and its incidence in disease is increasing. Dual β-lactam combinations act synergistically in …